Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Eurofins Discoverx Abl (M351T), active, 250 µg. (14-757M)
Supplier: Eurofins Discoverx 14757M
N-terminal 6xHis-tagged recombinant, human Abl, amino acids 27-end containing the M351T mutation. The Abl tyrosine kinase inhibitor STI571 is an effective therapy for stable-phase chronic myeloid leukemia patients. Many patients responding to STI571 later relapse due to a reactivation of Bcr-Abl activity. In certain cases this appears to correlate with the presence of the M351T mutation, which confers resistance to drug binding (Shah et al., (2002), Cancer Cell 2, 117-125). For detailed product information, visit www.discoverx.com/proteins.
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction